Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
Top
..
c19early.org COVID-19 treatment researchSelect treatment..Select..
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Baicalein-7-O-β-D glucopyranoside for COVID-19

Baicalein-7-O-β-D glucopyranoside has been reported as potentially beneficial for treatment of COVID-19. We have not reviewed these studies. See all other treatments.
Anshori et al., Uncovering the Therapeutic Potential of Propolis Extract in Managing Hyperinflammation and Long COVID‐19: A Comprehensive Bioinformatics Study, Chemistry & Biodiversity, doi:10.1002/cbdv.202401947
Hyperinflammation is significant factor in long COVID, impacting over 65 million post‐COVID‐19 individuals globally. Herbal remedies, including propolis, show promise in reducing severity and pro‐inflammatory cytokines. However, the natural pharmacological role of propolis in COVID‐19 management remains underexplored. Employing network pharmacology and in silico techniques, we assessed propolis extract's potential in countering SARS‐CoV‐2‐induced inflammation. We identified 80 flavonoids via LC‐MS/MS QTOF and employed 11 anti‐inflammatory drugs as references for inflammation target fishing. Utilizing in silico techniques encompassing target fishing, molecular docking, and dynamics, we examined propolis' effects. We identified 1105 gene targets connected to inflammation through multiple validated target predictors. By integrating SARS‐CoV‐2 DEGs from GSE147507 with these targets, we Identify precisely 25 inflammation‐COVID‐19‐associated propolis targets, including STAT1, NOS2, CFB, EIF2K2, NPY5R, and BTK. Enrichment analyses highlighted primary pharmacological pathways related to Epstein‐Barr virus infection and COVID‐19. Molecular docking validated Isokaempferide, Iristectorigenin B, 3’‐Methoxypuerarin, Cosmosin, and Baicalein‐7‐O‐β‐D glucopyranoside, which exhibited strong binding affinity and stability with relevant genes. Moreover, our findings indicate that propolis ligands could potentially suppress reactivation of Epstein‐Barr Virus infections in post‐COVID‐19 cases. These findings highlight propolis as potential supplement to alleviate inflammation in COVID‐19 patients and those with prolonged symptoms, requiring additional clinical validation for confirmation.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit